Alfayoumi, T., El-Rakshy, M., Awad Fayed, H., Khedr, G., Estefanos, E. (2022). RETROSPECTIVE STUDY CORRELATING BETWEEN CLINICAL STAGING, PATHOLOGIC STAGING AND MOLECULAR SUBTYPES OF BREAST CANCER. ALEXMED ePosters, 4(1), 47-48. doi: 10.21608/alexpo.2022.126569.1383
Tarek Abdel Halim Alfayoumi; Mohamed Tarek El-Rakshy; Haytham Mahmoud Awad Fayed; Gehan Abd El Atti Khedr; Emad Nagui Fouad Estefanos. "RETROSPECTIVE STUDY CORRELATING BETWEEN CLINICAL STAGING, PATHOLOGIC STAGING AND MOLECULAR SUBTYPES OF BREAST CANCER". ALEXMED ePosters, 4, 1, 2022, 47-48. doi: 10.21608/alexpo.2022.126569.1383
Alfayoumi, T., El-Rakshy, M., Awad Fayed, H., Khedr, G., Estefanos, E. (2022). 'RETROSPECTIVE STUDY CORRELATING BETWEEN CLINICAL STAGING, PATHOLOGIC STAGING AND MOLECULAR SUBTYPES OF BREAST CANCER', ALEXMED ePosters, 4(1), pp. 47-48. doi: 10.21608/alexpo.2022.126569.1383
Alfayoumi, T., El-Rakshy, M., Awad Fayed, H., Khedr, G., Estefanos, E. RETROSPECTIVE STUDY CORRELATING BETWEEN CLINICAL STAGING, PATHOLOGIC STAGING AND MOLECULAR SUBTYPES OF BREAST CANCER. ALEXMED ePosters, 2022; 4(1): 47-48. doi: 10.21608/alexpo.2022.126569.1383
RETROSPECTIVE STUDY CORRELATING BETWEEN CLINICAL STAGING, PATHOLOGIC STAGING AND MOLECULAR SUBTYPES OF BREAST CANCER
1Surgery Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
2Surgical Oncology Unit, Department of General Surgery Faculty of Medicine, Alexandria University, Alexandria, Egypt
3Department of Clinical Oncology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
4Surgical Oncology Unit, Department of General Surgery
Faculty of Medicine, Alexandria University, Alexandria, Egypt
Abstract
The biodiversity of breast cancer is reflected by the presence of different molecular subtypes. As medicine shifts to a more personalized approach, it is an important goal to correlate different molecular subtypes with clinical disease outcomes and targeted therapies as well as the diversity in systemic disease response, recurrence and survival rates.Breast cancer can be classified on a molecular basis into four different molecular subtypes depending on the expression of ER, PR, HER2 and Ki67. Molecular subtypes as new prognostic indicators have been received more and more attention. In these molecular subtypes, Luminal A subtype shows the best outcome, whereas HER2 overexpression and basal-like subtypes present the poorer outcome. 2. Aim of the work The primary aim of this study was to correlate between different clinicopathological staging pattern and various molecular subtypes of breast cancer. Also, the Secondary aim was to determine the disease-free survival and overall survival of different molecular breast cancer subtypes.
View on SCiNiTO
Top